Basilea Pharmaceutica Revenue vs. Current Valuation
| BPMUF Stock | USD 52.83 0.00 0.00% |
For Basilea Pharmaceutica profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Basilea Pharmaceutica to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Basilea Pharmaceutica AG utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Basilea Pharmaceutica's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Basilea Pharmaceutica AG over time as well as its relative position and ranking within its peers.
Basilea |
Basilea Pharmaceutica Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Basilea Pharmaceutica's current stock value. Our valuation model uses many indicators to compare Basilea Pharmaceutica value to that of its competitors to determine the firm's financial worth. Basilea Pharmaceutica AG is the top company in revenue category among its peers. It also is the top company in current valuation category among its peers reporting about 4.89 of Current Valuation per Revenue. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Basilea Pharmaceutica's earnings, one of the primary drivers of an investment's value.Basilea Revenue vs. Competition
Basilea Pharmaceutica AG is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is currently estimated at about 15.2 Billion. Basilea Pharmaceutica maintains roughly 148.12 Million in revenue contributing less than 1% to stocks in Biotechnology industry.
Basilea Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Basilea Pharmaceutica |
| = | 148.12 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Basilea Pharmaceutica |
| = | 724.26 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Basilea Current Valuation vs Competition
Basilea Pharmaceutica AG is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is currently estimated at about 77.06 Billion. Basilea Pharmaceutica maintains roughly 724.26 Million in current valuation contributing less than 1% to stocks in Biotechnology industry.
Basilea Pharmaceutica Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Basilea Pharmaceutica, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Basilea Pharmaceutica will eventually generate negative long term returns. The profitability progress is the general direction of Basilea Pharmaceutica's change in net profit over the period of time. It can combine multiple indicators of Basilea Pharmaceutica, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.
Basilea Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Basilea Pharmaceutica. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Basilea Pharmaceutica position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Basilea Pharmaceutica's important profitability drivers and their relationship over time.
Use Basilea Pharmaceutica in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Basilea Pharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Basilea Pharmaceutica will appreciate offsetting losses from the drop in the long position's value.Basilea Pharmaceutica Pair Trading
Basilea Pharmaceutica AG Pair Trading Analysis
The ability to find closely correlated positions to Basilea Pharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Basilea Pharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Basilea Pharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Basilea Pharmaceutica AG to buy it.
The correlation of Basilea Pharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Basilea Pharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Basilea Pharmaceutica moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Basilea Pharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Basilea Pharmaceutica position
In addition to having Basilea Pharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Basilea Pink Sheet
To fully project Basilea Pharmaceutica's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Basilea Pharmaceutica at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Basilea Pharmaceutica's income statement, its balance sheet, and the statement of cash flows.